Navigation Links
Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract
Date:6/24/2013

erance test results.

"We hope LX2761 may one day treat a large population of patients with diabetes, and potentially prediabetes, that may wish to avoid the urinary glucose excretion associated with SGLT2 inhibition in the kidney," said Brian Zambrowicz, Ph.D., executive vice president and chief scientific officer. "In addition, the synergy demonstrated with a DPP-4 inhibitor provides the mechanistic rationale to consider future combination therapies."

All presentations will be available for download from Lexicon's corporate website www.lexpharma.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's preclinical development of LX2761 and the potential therapeutic and commercial potential of LX2761.  This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's curren
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon To Present At The Goldman Sachs Global Healthcare Conference
2. Lexicon To Present At The Jefferies Global Healthcare Conference
3. Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results
5. Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
6. Lexicon to Report First Quarter Financial Results on May 10, 2013
7. Lexicon To Present At The Needham Healthcare Conference
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
9. Lexicon To Present At The BIO CEO & Investor Conference
10. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
11. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... t:slim® and t:flex™ Insulin Pumps, today announced the pricing ... its common stock at a price to the public ... from this offering are expected to be $56.3 million, ... offering expenses payable by Tandem. All of the shares ...
(Date:2/26/2015)... BEND, Ind. , Feb. 26, 2015  Mobility ... announce an agreement with Bank of America (NYSE: ... consumers nationwide to receive financing of the revolutionary MV-1 ... vehicle, designed from the ground up to provide safe ... Approved applicants can use their loan to purchase a ...
(Date:2/26/2015)... DALLAS , February 26, 2015 ... EU Outlook 2015: First -In- Class Innovations and ... Business for Large Cap Pharmaceutical Companies research report ... According to this Global Pharma US ... divested as productivity measurements, divestment of non-core assets ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3Global Pharma U.S. and EU Outlook 2015 Market Research Report 2Global Pharma U.S. and EU Outlook 2015 Market Research Report 3Global Pharma U.S. and EU Outlook 2015 Market Research Report 4
... 28, 2012   OncoSec Medical Incorporated (OTCBB: ONCS), ... ElectroOncology therapies to treat solid tumor cancers, today announced ... by the University of California San Francisco and the ... clinical trial evaluating OncoSec,s OMS ElectroImmunotherapy for ...
... from visual impairment due to autism, brain injury, stroke or ... a revolutionary new therapy program using specially designed games and ... Therapy Program uses a web-based application in which patients ... system dysfunction and strengthen visual skills. The application was created ...
Cached Medicine Technology:OncoSec Doses First Patient in Phase II Clinical Trial for Metastatic Melanoma 2OncoSec Doses First Patient in Phase II Clinical Trial for Metastatic Melanoma 3OncoSec Doses First Patient in Phase II Clinical Trial for Metastatic Melanoma 4New Therapy Program Allows Doctors to Prescribe Computer Games on iPad to Treat Visual Impairment 2
(Date:2/27/2015)... 27, 2015 Prescription Drug “Take-Back” ... Drug Enforcement Agency (DEA). Today, local ... to utilize the “Take-Back” guidelines for the proper ... , Eufaula Prescription Drug Disposal Event , The ... in Eufaula, Oklahoma as the “Take-Back” site for ...
(Date:2/27/2015)... a Feb. 12, 2015 news release by Verastem, Inc. ... killing cancer stem cells, has received orphan drug designation from ... the treatment of mesothelioma.* According to the release, orphan drug ... of drugs for the treatment of rare diseases. , ... Helbock, Founder of The Law Office of Melinda J. Helbock ...
(Date:2/27/2015)... Albany, NewYork (PRWEB) February 27, 2015 ... opportunities, and trends in the global celiac disease market. ... financial outlook, research and development activities, and investments. , ... indigestion of gluten damages the small intestine. Celiac disease ... one in every 100 people is affected by celiac ...
(Date:2/27/2015)... MA (PRWEB) February 27, 2015 A fireplace ... 20 percent of its heat through the chimney’s flue when ... energy issue that Tamarack Technologies has solved with the introduction ... is actually a PVC pillow measuring 18" in diameter when ... or zero-clearance fireplace just below the damper. This size unit ...
(Date:2/27/2015)... 2015 According to the Center ... 38 million children and adolescents participate in sports ... a result of this growing number, new and ... and square footage creating a need for preventative ... , "Athletic facilities are hosting a record ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Promotes Local Prescription Drug Take Back Day 2Health News:Narconon Arrowhead Promotes Local Prescription Drug Take Back Day 3Health News:New Drug Receives FDA Approval as Orphan Drug for the Treatment of Mesothelioma 2Health News:New Drug Receives FDA Approval as Orphan Drug for the Treatment of Mesothelioma 3Health News:Global Celiac Disease Market Counts on Drug Launch for Growth 2Health News:Global Celiac Disease Market Counts on Drug Launch for Growth 3Health News:New DraftStopper from Tamarack Technologies Stops Heat Loss When Fireplace Not in Use 2Health News:Rise of Students Participating in Sports Creates Need for Preventative Maintenance to Gymnasium Equipment in Athletic Facilities 2Health News:Rise of Students Participating in Sports Creates Need for Preventative Maintenance to Gymnasium Equipment in Athletic Facilities 3
... Fox Chase Cancer Center have demonstrated that a protein called ... forms of breast cancer to grow. Their findings, based on ... presented in a recent issue of Cancer Research , ... been able to present evidence that directly demonstrates reduced levels ...
... side effects, say UK researchers, , FRIDAY, Oct. 2 ... does not increase the risk for self-harm or depression, ... the U.S. Food and Drug Administration mandated that the ... that people who use it face increased risk for ...
... ... , ... 2009 -- Finding information to provide essential and practical aid and care during serious situations ... may not be able to deliver a timely response, or to administer self-care without a ...
... Hickman, United Feather & Down,s Senior Vice Present of Sales ... of Marketing, list their top sleep and beauty tips. , ... than water, and its super emollient qualities help it moisturize ... to your skin to help you awaken refreshed and rejuvenated. ...
... , DALLAS, Oct. 2 Ben DuBose, of DuBose Law Firm, PLLC, ... Texas Monthly as one of the select "Texas Super Lawyers" in ... this year, Mr. DuBose was chosen as one of the "Best Lawyers ... by Law & Politics Media and Texas Monthly ...
... SUMMIT, Mo., Oct. 2 R&D/Leverage,s enhanced medical and ... roof - continue to expand in anticipation of further ... President - Engineering. , According to Wescoat, the company,s ... staff, new lean initiatives and quality-control protocols and world-class ...
Cached Medicine News:Health News:NEDD9 protein supports growth of aggressive breast cancer 2Health News:Study Counters Warnings on Quit-Smoking Drug 2Health News:VisionSync Launches a Smart iPhone First Aid App, iMobile Care 2Health News:VisionSync Launches a Smart iPhone First Aid App, iMobile Care 3Health News:Ten from Two: Top Sleep and Beauty Tips from the Experts 2Health News:Ten from Two: Top Sleep and Beauty Tips from the Experts 3Health News:'Texas Monthly' Recognizes Ben DuBose Among the Super Lawyers of Texas 2Health News:R&D/Leverage Heightens Investment in Medical and Silicone Mold Manufacturing 2Health News:R&D/Leverage Heightens Investment in Medical and Silicone Mold Manufacturing 3
... Are Available In Two Models: One Is Direct ... Jaws Close. The Other Model Is Reverse ... Compressed The Jaws Open., ,The Forceps Are 22g, ... Through A 1.1mm Incision. These Forceps Allow The ...
... Allows Use Through A 1-Millimeter Incision.,Special ... Approach To The Incision.,Cystotome Tips Are ... Initiate And Complete A Circular Tear.,Titanium ... Improved Ergonomic Feel. Ideal For Bi-Manual ...
... fiber optic for homogenous illumination. ... bright halogen illumination for clear ... canal. Lithium-ion batteries with ... rheostat for fine control of ...
All Keeler otoscopes have bright halogen illumination for clear and accurate visualization of aural canal. Lithium-ion batteries with quick recharge capability. Ring rheostat for fine control of il...
Medicine Products: